https://www.kinarus.com https://www.kinarus.com/about/about-kinarus.html https://www.kinarus.com/about/leadership.html https://www.kinarus.com/about/board-of-directors.html https://www.kinarus.com/about/partners.html https://www.kinarus.com/innovation-and-pipeline/therapeutic-approach.html https://www.kinarus.com/innovation-and-pipeline/pipeline.html https://www.kinarus.com/disease-focus/covid-19.html https://www.kinarus.com/disease-focus/age-related-macular-degeneration.html https://www.kinarus.com/disease-focus/idiopathic-pulmonary-fibrosis.html https://www.kinarus.com/investors/financials.html https://www.kinarus.com/news.html https://www.kinarus.com/contact.html https://www.kinarus.com/index_php/contact.html https://www.kinarus.com/location.html https://www.kinarus.com/disclaimer.html https://www.kinarus.com/privacy-policy.html https://www.kinarus.com/about/leadership/5-alexander-bausch.html https://www.kinarus.com/about/leadership/30-corinne-peter.html https://www.kinarus.com/about/leadership/7-viktor-boerlin.html https://www.kinarus.com/about/leadership/10-matthew-wright.html https://www.kinarus.com/about/leadership/8-urs-breitenstein.html https://www.kinarus.com/about/board-of-directors/11-dr-alexander-bausch.html https://www.kinarus.com/about/board-of-directors/13-roger-meier.html https://www.kinarus.com/about/board-of-directors/12-silvio-inderbitzin.html https://www.kinarus.com/about/board-of-directors/36-eugene-tierney.html https://www.kinarus.com/MA.html https://www.kinarus.com/MD.html https://www.kinarus.com/NA.html https://www.kinarus.com/ND.html https://www.kinarus.com/SA.html https://www.kinarus.com/SD.html https://www.kinarus.com/about-us/advisors.html https://www.kinarus.com/about-us/advisors/dr-viktor-boerlin-m-d.html https://www.kinarus.com/about-us/advisors/prof-hendrik-p-n-scholl-m-d.html https://www.kinarus.com/about-us/board-of-directors.html https://www.kinarus.com/about-us/board-of-directors/dr-alexander-bausch-ph-d-mte-imd.html https://www.kinarus.com/about-us/board-of-directors/dr-hari-kumar-ph-d.html https://www.kinarus.com/about-us/board-of-directors/dr-silvio-inderbitzin-ph-d.html https://www.kinarus.com/about-us/board-of-directors/dr-silvio-inderbitzin.html https://www.kinarus.com/about-us/board-of-directors/eugene-tierney.html https://www.kinarus.com/about-us/board-of-directors/guenter-graubach.html https://www.kinarus.com/about-us/board-of-directors/marian-borovsky.html https://www.kinarus.com/about-us/board-of-directors/roland-rutschmann.html https://www.kinarus.com/about-us/kinarus-story.html https://www.kinarus.com/about-us/management-team.html https://www.kinarus.com/about-us/management-team/claudia-berger.html https://www.kinarus.com/about-us/management-team/dr-alexander-bausch-ph-d-mte-imd.html https://www.kinarus.com/about-us/management-team/dr-matthew-wright-ph-d.html https://www.kinarus.com/about-us/management-team/dr-thierry-fumeaux-m-d-mba-imd.html https://www.kinarus.com/about-us/management-team/subhasis-roy.html https://www.kinarus.com/about/board-of-directors/51-dr-hari-kumar-ph-d.html https://www.kinarus.com/about/history.html https://www.kinarus.com/about/leadership/50-dr-thierry-fumeaux-m-d-mba-imd.html https://www.kinarus.com/about/leadership/6-claudia-berger.html https://www.kinarus.com/board-of-directors.html https://www.kinarus.com/board-of-directors/11-dr-alexander-bausch.html https://www.kinarus.com/board-of-directors/12-silvio-inderbitzin.html https://www.kinarus.com/board-of-directors/13-roger-meier.html https://www.kinarus.com/board-of-directors/36-eugene-tierney.html https://www.kinarus.com/cookie-policy.html https://www.kinarus.com/disease-areas/age-related-macular-degeneration.html https://www.kinarus.com/disease-areas/covid-19.html https://www.kinarus.com/empty-testseite.html https://www.kinarus.com/imprint.html https://www.kinarus.com/management-team.html https://www.kinarus.com/management-team/10-matthew-wright.html https://www.kinarus.com/management-team/30-corinne-peter.html https://www.kinarus.com/management-team/5-alexander-bausch.html https://www.kinarus.com/management-team/6-claudia-berger.html https://www.kinarus.com/management-team/7-viktor-boerlin.html https://www.kinarus.com/management-team/8-urs-breitenstein.html https://www.kinarus.com/press-release.html https://www.kinarus.com/press-release/49-press-release-january-21st.html https://www.kinarus.com/press-release/52-first-hospitalized-covid-19-patient-dosed-with-kin001-in-phase-2-study.html https://www.kinarus.com/press-release/54-kinarus-further-strengthens-its-leadership-with-two-reputed-industry-experts.html https://www.kinarus.com/press-release/55-unterschaetzte-coronamedikamente.html https://www.kinarus.com/press-release/56-big-pharma-bring-die-power-startups-liefern-die-kreativitaet.html https://www.kinarus.com/press-release/57-signature-of-a-memorandum-of-understanding-with-perfect-holding-sa.html https://www.kinarus.com/press-release/60-preclinical-data-confirm-triple-mechanism-of-action-of-lead-compound-kin001-in-covid-21.html https://www.kinarus.com/press-release/61-kinarus-sind-mehr-als-eine-wette-auf-ein-coronamittel.html https://www.kinarus.com/press-release/62-kinarus-secures-chf-57-million-capital-commitment.html https://www.kinarus.com/press-release/63-kinarus-receives-7-million-chf-grant-from-the-swiss-federal-funding-programme-for-covid-19-medicines.html https://www.kinarus.com/press-release/65-kinarus-announces-signing-of-a-transaction-agreement-with-perfect-holding.html https://www.kinarus.com/press-release/66-kinarus-receives-positive-recommendation-from-dsmb-to-continue-phase-2-trial-in-covid-19.html https://www.kinarus.com/press-release/67-kinarus-shareholders-approve-reverse-takeover-by-perfect-holding-sa.html https://www.kinarus.com/press-release/68-kinarus-receives-grant-of-key-u-s-patent-for-its-lead-therapeutic-candidate.html https://www.kinarus.com/press-release/69-positive-preclinical-data-for-kin001-in-wet-age-related-macular-degeneration-plans-for-clinical-development.html https://www.kinarus.com/programs-and-pipeline/clinical-development-pipeline.html https://www.kinarus.com/programs-and-pipeline/therapeutic-approach.html https://www.kinarus.com/ir-sub/index.html https://www.kinarus.com/ir-sub/2023-agm.html https://www.kinarus.com/ir-sub/agm.html https://www.kinarus.com/ir-sub/analyst-coverage.html https://www.kinarus.com/ir-sub/analyst-coverage/header-kinarus-image-05-2.html https://www.kinarus.com/ir-sub/author/admin.html https://www.kinarus.com/ir-sub/category/uncategorized.html https://www.kinarus.com/ir-sub/corporate-governance.html https://www.kinarus.com/ir-sub/download-1.html https://www.kinarus.com/ir-sub/download-2.html https://www.kinarus.com/ir-sub/edison-logo.html https://www.kinarus.com/ir-sub/equity-logo.html https://www.kinarus.com/ir-sub/favicon-32x32.html https://www.kinarus.com/ir-sub/financial-calendar.html https://www.kinarus.com/ir-sub/financial-calendar/header-kinarus-image-05.html https://www.kinarus.com/ir-sub/financial-news.html https://www.kinarus.com/ir-sub/financial-reporting.html https://www.kinarus.com/ir-sub/financial-reporting/_page-2.html https://www.kinarus.com/ir-sub/half-year-report.html https://www.kinarus.com/ir-sub/half-year-report/_page-2.html https://www.kinarus.com/ir-sub/hello-world.html https://www.kinarus.com/ir-sub/investors-and-media.html https://www.kinarus.com/ir-sub/ir-contact-service.html https://www.kinarus.com/ir-sub/kinarus-favicon.html https://www.kinarus.com/ir-sub/logo.html https://www.kinarus.com/ir-sub/mt-sample-background.html https://www.kinarus.com/ir-sub/news/courts-of-basel-stadt-have-revoked-bankruptcy-of-kinarus-therapeutics-holding-ag/4c229bd3-be5e-4086-a729-f21570941bc7.html https://www.kinarus.com/ir-sub/news/einladung-zur-ausserordentlichen-generalversammlung-2024/c3e5ae4f-38be-4e66-a58f-b0db93d73aa6.html https://www.kinarus.com/ir-sub/news/extraordinary-general-meeting-of-kinarus-holding-approved-all-resolutions-relating-to-the-envisaged-business-combination/212d5d54-ff6f-4c69-9b4e-98edec2857ce.html https://www.kinarus.com/ir-sub/news/first-hospitalized-covid-19-patient-dosed-with-kin001-in-phase-2-study/68c6d355-9977-4c1e-8b87-743806f9eff6.html https://www.kinarus.com/ir-sub/news/invitation-to-the-extraordinary-general-meeting/192f3d6e-9855-4f78-86b2-15b2b21c70e2.html https://www.kinarus.com/ir-sub/news/kinarus-ag-first-hospitalized-covid-19-patient-dosed-with-kin001-in-phase-2-study/cc01f8b9-2eb7-4650-a8ba-ee4b747ecca8.html https://www.kinarus.com/ir-sub/news/kinarus-announces-signing-of-a-transaction-agreement-with-perfect-holding/e31d2569-576d-47e5-8756-5f93ae290997.html https://www.kinarus.com/ir-sub/news/kinarus-announces-the-issuance-of-convertible-notes-of-up-to-chf-20-million-to-an/d21bd39a-69bf-4bb3-9e41-7594223182d4.html https://www.kinarus.com/ir-sub/news/kinarus-appoints-thierry-fumeaux-md-as-chief-medical-officer/e0bf40f8-d6a7-4c71-9b7c-164957b8c689.html https://www.kinarus.com/ir-sub/news/kinarus-further-strengthens-its-leadership-with-two-reputed-industry-experts/3552510e-425a-4c9b-ad79-bba3f41eec20.html https://www.kinarus.com/ir-sub/news/kinarus-receives-7-million-chf-grant-from-the-swiss-federal-funding-programme-for-covid-19-medicines/fccbfd88-7a58-4141-a981-1ddd64656089.html https://www.kinarus.com/ir-sub/news/kinarus-receives-grant-of-key-u-s-patent-for-its-lead-therapeutic-candidate/54a5a83b-26e9-4a59-87ac-163bec67bfe6.html https://www.kinarus.com/ir-sub/news/kinarus-receives-positive-recommendation-from-dsmb-to-continue-phase-2-trial-in-covid-19/2e00e377-9d80-4f9a-b016-26f75ac2e03d.html https://www.kinarus.com/ir-sub/news/kinarus-receives-uspto-notice-of-allowance-for-lead-therapeutic-candidate-kin001/bd614aa3-86b3-4251-8b8c-89d22ed9a4ff.html https://www.kinarus.com/ir-sub/news/kinarus-secures-chf-57-million-capital-commitment/9506726f-c1a7-4d40-8755-58e0d77397c5.html https://www.kinarus.com/ir-sub/news/kinarus-shareholders-approve-reverse-takeover-by-perfect-holding-sa/dc96aa15-89f8-40df-a169-224a96edf09d.html https://www.kinarus.com/ir-sub/news/kinarus-therapeutics-announces-discontinuation-of-the-phase-2-kinetic-study-of-kin001-in-hospitalized-covid-19/8eeceb93-3d0f-4e29-aa67-c4b4d290735c.html https://www.kinarus.com/ir-sub/news/kinarus-therapeutics-announces-name-change-and-commences-trading-on-the-six-swiss-exchange-under-ticker/8482d499-ae2f-4798-be60-f9ac8c18d668.html https://www.kinarus.com/ir-sub/news/kinarus-therapeutics-announces-personnel-changes/21e6be1a-2dd0-45e6-85e8-d40e21d99ec3.html https://www.kinarus.com/ir-sub/news/kinarus-therapeutics-engages-great-health-companion-group-to-explore-partnerships-in-china/207e91a8-92f6-412c-b9f0-8792dc3d65ca.html https://www.kinarus.com/ir-sub/news/kinarus-therapeutics-group-reports-2022-annual-results/d3d99d06-0039-4fe9-bb1d-6ed73efdd727.html https://www.kinarus.com/ir-sub/news/kinarus-therapeutics-group-reports-first-half-2023-financial-results/be2cec63-39ed-45f6-ad33-250836bb8e52.html https://www.kinarus.com/ir-sub/news/kinarus-therapeutics-has-decided-to-file-for-bankruptcy/19de6eb7-5f5c-4b3f-b662-7e26ea833557.html https://www.kinarus.com/ir-sub/news/kinarus-therapeutics-holding-ag-in-liquidation-and-curatis-ag-propose-to-combine-companies-and-reverse/7ec9feb6-2bc8-4702-ba96-f2b940a0ffbc.html https://www.kinarus.com/ir-sub/news/kinarus-therapeutics-holding-ag-kinarus-receives-deadline-extension-from-ser-for-publication-of-its-2022/4be84988-8214-4f7c-95d9-3b431992deeb.html https://www.kinarus.com/ir-sub/news/kinarus-therapeutics-initiates-kin001-phase-ii-kinfast-clinical-trial-in-covid-19-outpatients/4b0f88c5-ca81-4927-8f5b-6063d56ced7f.html https://www.kinarus.com/ir-sub/news/kinarus-therapeutics-kin001-shows-strong-antiviral-activity-against-sars-cov-2-and-variants-of-concern/8b791a51-1a44-4cc1-b58b-c8c22706a711.html https://www.kinarus.com/ir-sub/news/kinarus-therapeutics-kin001-shows-strong-antiviral-activity-against-sars-cov-2-omicron-subvariants-ba-2-and-ba-5/27c30b2f-0aff-49b4-9826-562f9d624bf0.html https://www.kinarus.com/ir-sub/news/kinarus-therapeutics-phase-2-kinfast-covid-19-clinical-trial-progress-update/1d0dda7e-92a6-425d-a862-a30832611210.html https://www.kinarus.com/ir-sub/news/kinarus-therapeutics-provides-strategic-update/65046611-5521-4003-87cc-6adca482e12d.html https://www.kinarus.com/ir-sub/news/kinarus-therapeutics-publishes-invitation-to-the-2023-annual-general-meeting/b0dfef3f-167c-4395-8770-bbedd069fefb.html https://www.kinarus.com/ir-sub/news/kinarus-therapeutics-reports-h1-2022-financial-results-and-provides-corporate-update/4d527ca6-76ec-4967-bf89-02942e57e853.html https://www.kinarus.com/ir-sub/news/kinarus-therapeutics-reports-key-unaudited-full-year-2022-figures/3710a926-7bc1-435e-883d-4016ba1137ef.html https://www.kinarus.com/ir-sub/news/kinarus-therapeutics-reports-preclinical-data-in-lung-fibrosis-and-discloses-clinical-development-plan/c24393e4-0874-4d0d-a2f3-ba26abac57ae.html https://www.kinarus.com/ir-sub/news/kinarus-therapeutics-shareholders-approve-all-board-proposals-at-the-2023-annual-general-meeting/53bfa93c-88ca-4abd-9d7c-32479660c3b7.html https://www.kinarus.com/ir-sub/news/kinarus-therapeutics-signed-chf1-5-million-convertible-loan-agreement-with-chaodian-hangzhou-investment-management/c9529824-8712-4fcc-941a-969275624766.html https://www.kinarus.com/ir-sub/news/kinarus-therapeutics-signed-licensing-agreement-to-extend-cash-for-operations/e9b74e75-3f43-4b78-8f0e-258cf3b7ba82.html https://www.kinarus.com/ir-sub/news/kinarus-therapeutics-signed-subordinated-bridge-loans-to-ensure-further-liquidity/c99b5907-69d5-4abd-82b0-fefb880ebe41.html https://www.kinarus.com/ir-sub/news/kinarus-therapeutics-to-hold-webinar-on-a-new-approach-to-treating-covid-19/f678890c-5710-4fb6-b842-930af898b43f.html https://www.kinarus.com/ir-sub/news/kinarus-therapeutics-to-host-kol-event-on-monday-june-27-to-discuss-therapies-in-wet/035a23e4-3c12-4bda-addb-df9f73939451.html https://www.kinarus.com/ir-sub/news/minutes-of-the-extraordinary-general-meeting-of-shareholders/211dcc96-4641-45ab-9571-566bc54e89f2.html https://www.kinarus.com/ir-sub/news/perfect-holding-completes-reverse-takeover-transaction-with-kinarus/3da527e7-54a4-425a-be38-b9edb3a3a4cf.html https://www.kinarus.com/ir-sub/news/positive-preclinical-data-for-kin001-in-wet-age-related-macular-degeneration-plans-for-clinical-development/7f296fa5-0126-4143-a992-c1604c059670.html https://www.kinarus.com/ir-sub/news/preclinical-data-confirm-triple-mechanism-of-action-of-lead-compound-kin001-in-covid-19/b8484a79-4425-4e88-bfc3-4737569acd10.html https://www.kinarus.com/ir-sub/news/publication-of-unaudited-financial-statements-of-kinarus-therapeutics-holding-ag-only-for-fy2023/dfc09163-8137-434c-a831-b3d68c7bff85.html https://www.kinarus.com/ir-sub/news/signature-of-a-memorandum-of-understanding-with-perfect-holding-sa/474e64ad-f12d-407a-af6e-9e6b88a00d7b.html https://www.kinarus.com/ir-sub/press-releases.html https://www.kinarus.com/ir-sub/reports-presentations.html https://www.kinarus.com/ir-sub/reports-presentations/perfect-holding-sa-historical-information.html https://www.kinarus.com/ir-sub/reports-presentations/perfect-holding-sa-historical-information/_page-2.html https://www.kinarus.com/ir-sub/reports-presentations/_page-2.html https://www.kinarus.com/ir-sub/successful-subscription-to-ir-newsletter.html https://www.kinarus.com/ir-sub/webcast-presentations.html https://www.kinarus.com/index_htm.html https://www.kinarus.com/about-us.html https://www.kinarus.com/programs-and-pipeline.html https://www.kinarus.com/disease-areas.html https://www.kinarus.com/investors-and-media.html https://www.kinarus.com/about-us/adivisors.html https://www.kinarus.com/en/about-us/board-of-directors.html